Premium
CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice
Author(s) -
Weeratna Risini,
Comanita Lacrimioara,
Davis Heather L
Publication year - 2003
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1046/j.1440-1711.2003.01135.x
Subject(s) - alum , antigen , adjuvant , cpg oligodeoxynucleotide , antibody , immunology , virology , medicine , microbiology and biotechnology , chemistry , biology , biochemistry , gene expression , dna methylation , organic chemistry , gene
We have evaluated alum, immunostimulatory cytosine guanine dinucleotide‐containing oligodeoxynucleotides (CPG ODN), and an alum/CPG ODN combination as adjuvants with hepatitis B surface antigen, to compare their potential to allow lower doses of antigen to be used for induction of humoral responses. BALB/c mice were immunized by intramuscular injection with 0.01, 0.1 or 1.0 µg recombinant hepatitis B surface antigen without adjuvant or with alum and/or CPG ODN added. When given without adjuvant or with alum, each 10‐fold decrease in amount of antigen resulted in a similarly reduced titre of antibody against hepatitis B surface antigen. In contrast, CPG ODN, on its own or combined with alum, allowed high anti‐hepatitis B surface antigen titres even with a 1000‐fold reduction in amount of antigen. These findings may have important immunological and economical consequences for vaccine development.